Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Therapure Biopharma to Acquire Plasma Protein Purification Technology

Published: Monday, December 09, 2013
Last Updated: Sunday, December 08, 2013
Bookmark and Share
Therapure and Upfront have entered into an agreement.

Therapure Biopharma Inc. and Upfront Chromatography A/S have announced that they have entered into an agreement for Therapure to acquire the assets and associated business related to human plasma fractionation from Upfront.

Upfront has developed over the last 15 years, a proprietary protein purification technology, based on Expanded Bed Adsorption (EBA) chromatography which offers significant advantages over to other purification technologies.

As a result of the acquisition, Therapure gains exclusive rights for the commercialization of the Upfront technology relevant to the human plasma fractionation field. Therapure will continue to develop and market this technology under the new trademark PlasmaCap EBA.

Nick Green, CEO of Therapure, commented: “The acquisition of the PlasmaCap EBA technology is an important addition to Therapure’s purification portfolio. With PlasmaCap EBA, Therapure now possesses a technology to capture therapeutic plasma proteins that is highly efficient and less damaging to the end product compared to conventional methods of fractionation. Ultimately PlasmaCap EBA allows for a more cost-effective process to manufacture plasma proteins. Therapure has established an excellent reputation as a biologics contract development and manufacturing organization (CDMO) with integrated services including plasma protein purification. The acquisition of this technology will further support Therapure’s reputation as a leader in the biologics manufacturing sector in general, and as a global leader in terms of plasma protein purification. We feel strongly that this technology can add significant value to our clients as they seek to optimize their manufacturing processes and associated economics.”

Upfront divested their pharmaceutical business unit in April 2010 to DSM Biologics, and is now focusing on their BioMine business line, where the technology is offered to the food/feed ingredients business for extraction of food grade proteins.

“We see this additional divestment of our technology to Therapure as a major milestone for Upfront”, commented Michael Pålsson, CEO of Upfront. “It is yet another significant blue-stamp of our technology, driven by its value creation in the capture of high value proteins. We are now ready to focus 100% on our BioMine business which aims to valorize under-utilized side and waste streams from the food, feed and biofuel industries. There is a broad range of food and feed industries in the world with large volumes of side and waste streams containing valuable proteins. We are able to help these manufacturers get more value out of these streams, and at the same time we see a growing, global need for alternative protein sources to feed the world’s population.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Therapure Biopharma Awarded US Government Contract
DoD contract to manufacture materials for anti-nerve gas agent.
Thursday, June 20, 2013
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Personality Traits, Psychiatric Disorders Linked to Specific Genomic Locations
Researchers have unearthed genetic correlations between personality traits and psychiatric disorders.
Forensic 3D Documentation of Skin Injuries
In this study, the validity of using photogrammetry for documenting injuries in a pathological context was demonstrated.
3-D Printed Dog’s Nose Improves Vapor Detection
By mimicking how dogs get their whiffs, a team of government and university researchers have demonstrated that “active sniffing” can improve by more than 10 times the performance of current technologies that rely on continuous suction to detect trace amounts of explosives and other contraband.
New Markers for Forensic Body-fluid Identification
University of Bonn researchers have successfully identified specific Micro-RNA signatures to help forensically identify body fluids.
Genetics Control Regenerative Properties Of Stem Cells
Researchers define how genetic factors control regenerative properties of blood-forming stem cells.
Major Neuroscience Initiative Launched
Tianqiao and Chrissy Chen Institute invest $115 million to further expand neuroscience research, while Caltech construct $200 million biosciences complex.
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!